Sage trig­gers an­oth­er burst of in­vestor en­thu­si­asm as oral de­pres­sion drug scores in PhII

Sage Ther­a­peu­tics shares are once again rock­et­ing up this morn­ing, this time based on pos­i­tive re­sults from a small Phase II study of an oral ver­sion of their de­pres­sion ther­a­py.

Long one of the most volatile stocks in biotech, Sage says that SAGE-217 clear­ly hit the goal post for sta­tis­ti­cal sig­nif­i­cance in ma­jor de­pres­sive dis­or­der, achiev­ing a 64% suc­cess rate in achiev­ing clin­i­cal re­mis­sion on a com­mon­ly used score for de­pres­sion against 23% on a place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.